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1. Introduction
  Cell movement through tissue plays a crucial role in 
cancer progression, and requires a series of distinct but 
concerted biological events in which the actin cytoskeleton 
play an essential role. The actin-mediated interactions 
not only perform mechanical functions supporting cell 
and tissue architecture but also transduce specific signals 
affecting fundamental biological functions[1,2]. Cytoskeleton 
is involved in all the aspects of cell behavior, which 
includes cancer and other human diseases[3,4]. The drugs 
that targets actin cytoskeleton serve as potential therapeutic 
agents in the treatment of cancer[5,6]. Current anticancer 
treatments aim to target tumor cells’ ability to proliferate. 
Therapeutic drugs that target cell motility and invasion thus 
appear to be important to combat cancer. The microtubule 
affecting drugs are already considered to be promising tools 
to combat metastatic cancers[7,8]. 
  Protein complexes play crucial role in several cellular 
functions, and heat shock proteins (Hsps) are central 
regulators of protein homeostasis. Very little information is 
available on Hsp dependency on actin and related folding 
complexes. Hsp60 homologue in the eukaryotes, TCP-1 is 
identified as a tubulin and actin binding protein[9,10]. Hsp70 
was characterized as a microtubule-associated protein and 
is involved in tubulin polymerization. The Hsc70 cognate 
form found co-precipitated with both polymerized and 
depolymerized tubulin[11]. Small heat shock proteins help 
in recovery of actin[12]. The Hsp90 chaperone also thought 
to be involved in both microtubule-based functions and 
intermediate filaments[13,14]. Among different Hsps, Hsp90 
chaperone is an abundant, ubiquitously expressed and 
highly conserved protein that is involved in a diverse array 
of cellular processes[15,16]. In mammalian cells, Hsp90 
is associated with proto-oncogene kinases thus helps in 
tumor progression and cell survival. For this reason Hsp90 
emerged as an exciting new target for the development of 
innovative cancer therapeutics[17,18]. Most of the antitumor 
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effects of Hsp90 inhibition using geldanamycin and its 
analogue 17-(Allylamino)-17-demethoxygeldanamycin 
(17AAG) were attributed either to induce cytostasis or 
apoptosis. Therefore, a possible interaction between Hsp90 
and actin polymers can be anticipated. 
  Remodeling of cytoskeleton usually results in loss of cell-
cell communication and migration[19,20]. Further it was shown 
that disruption of microfilaments/intermediate filaments but 
not disruption of microtubules affects the metastatic ability 
of tumor cells. Heat shock proteins binding to cytoskeletal 
proteins has been shown to assist in trafficking of cellular 
proteins[21,22]. Although Hsp90 is localized to microtubules 
and microfilaments in live cells, though actin interferes 
with Hsp90 adenosine tri-phosphate (ATP) binding in vitro, 
a direct association between cellular actin with Hsp90 is 
not known. The aim of the present study was to examine 
the effect of Hsp90 inhibition on actin-cytoskeleton of 
tumor cells and to understand the significance of Hsp90 
interactions with filamentous actin. We demonstrate 
that Hsp90 is indispensible for maintenance of actin-
cytoskeleton in tumor cells.
2. Materials and methods
2.1. Materials
  17AAG was purchased from Invivogen and Sigma 
respectively. Stock solutions of 17AAG (2 mg/mL) in DMSO 
and curcumin (10 mg/mL) in methanol were prepared. 
Dulbecco’s Modified Eagles Medium (DMEM), fetal 
calf serum (FCS), penicillin, streptomycin, trypsin were 
purchased from GIBCO BRL. 4’,6-diamidino-2-phenylindole 
(DAPI), rhodamine phalloidin, Oregon green phalloidin were 
from Invitrogen-Molecular Probes. All other chemicals were 
from Sigma Chemical Company unless otherwise indicated.
2.2. Cell culture maintenance and treatments
  Human neuroblastoma tumor cells (IMR32), rat fibroblasts 
(F111) and human cervical cancer cells (HeLa) were 
maintained in DMEM containing 10% FCS, penicillin (100 
U/mL), and streptomycin (50 毺g/mL) in a humidified 
atmosphere of 95% air and 5% CO2 at 37 曟. The exponentially 
growing tumor cells (1伊106/mL) in the complete medium 
were used for drug treatments. 
2.3. The morphological analysis and laser scanning confocal 
microscopy
  Cells grown on cover glass (Fisher Scientifics, 22 mm伊
22 mm) and treated with different drugs for different time 
intervals were visualized under phase contrast microscope 
(Nikon, TMS) attached to a 35 mm camera and photographed at 
10伊 magnification for morphological analysis. For confocal 
microscopic analysis, cells were washed and fixed with 4% 
formaldehyde (10 min; room temperature) and permeabilized 
with 0.01% Triton X-100 (5 min). The actin cytoskeleton 
was stained using either rhodmaine labelled phalloidin or 
Oregon green labelled phalloidin (15 min; room temperature) 
and mounted onto the glass slide(s) along with ProLong 
Antifade reagent containing DAPI (50 nM; Invitrogen). The 
edges of the cover glasses were sealed to the slide with 
nail paint and observed under laser scanning confocal 
microscopy (Olympus FV500 microscope).
2.4. Lactate dehydrogenase measurement
  The activity of lactate dehydogenase (LDH) was measured 
using the direct spectrophotometric assay in the presence of 
pyruvate and NADH. Tumor cells were treated with different 
concentrations of 17AAG for 6 h and subjected to 0.001% 
Brij58 treatment for another 10 min, centrifuged at low 
speed (3 000 rpm; 5 min) using Remi table top centrifuge. 
The supernatant was collected and used for measuring the 
per cent LDH release from the cytosol. Complete cell lysis 
was achieved sonicating cells for 3 min, in three intervals, 
on ice. In 2 mL of 50 mM Hepes buffer (pH 7.4) containing 
30 毺M pyruvate and 30 毺M NADH, 10 毺L of supernatant 
was added, and changes in optical density was measured at 
340 nm for 5 min. The percent LDH release was calculated 
by dividing the activity of LDH in the supernatant by the 
LDH activity measured after complete lysis achieved by 
sonication.
2.5. Purification of Hsp90 from rat liver
  The 90 kDa heat shock protein was purified from rat liver 
with consecutive chromatographies on Butyl-Sepharose 4B, 
DEAE-Sepharose Fast Flow, Sephacryl S-200 and Econo-
Pac HTP. The purity of these Hsp90 preparations was more 
than 95% as judged by silver staining of SDS polyacrylamide 
gels. Protein concentrations were determined according to 
Bradford method. N-terminal ATP-binding region deleted, 
bacterially expressed recombinant chicken Hsp90 protein 
was a kind gift from Dr. Yoshihiko Miyata, Japan.
2.6. Purification of Hsp90 from tumor cells
  Hsp90 was purified from tumor cells in a single step ATP-
sepharose chromatography. Two milliliter syringe was 
packed with pre-swollen ATP-sepharose, blocked with 
bovine serum albumin (1 mg/mL) to prevent non-specific 
binding to the sepharose matrix. Columns were pre-treated 
with ATP and NaCl (10 mM and 0.5 M respectively) and re-
equilibrated with several bead volumes of binding buffer 
provided by the manufacturer. The crude cell lysates of 
control and 17AAG treated neuroblastoma cell extracts were 
passed over the column, and eluted with 10 mM ATP and 
0.5 M NaCl. Hsp specific enhanced protein binding was 
achieved by omitting ADP from the binding buffer. Hsps 
including the major fraction of Hsp90 were eluted out with 
10 mM ADP buffer, checked for its chaperone activity and 
used for F-actin binding assay.
2.7. Purification of actin from rabbit skeletal muscle
  Actin was purified from rabbit skeletal muscle. Purified 
actin was always stored on ice at 4 曟. The monomeric actin 
was polymerized for 1 h at room temperature in 5 mM Tris-
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Cl, 50 mM KCl, 5 mM 毬-mercaptoethanol, 2 mM MgCl2, 
and 1 mM ATP. The filamentous actin (F-actin) stock 
solution (23 毺M) was stored at 4 曟. The state of the actin 
was evaluated by SDS-PAGE and coomassie blue staining.
2.8. Hsp90-actin binding assay (co-precipitation and 
sedimentation) 
  Hsp90 and F-actin were used in 5 毺g and 25 毺g (1:5 
ratio) respectively in 50 毺L binding buffer containing 200 毺
M KCl, 5 毺M MgCl2, 2 毺M DTT, and 40 毺M Hepes (pH 
6.8). The reaction mixture was incubated for 45 min at 
room temperature and centrifuged (Beckmen Centriguge, 
100.1 rotor) at 53 000 rpm for 1 h at 4 曟. Supernatant and 
pellet fractions were separated, 6 毺L supernatant was 
directly mixed with Laemmli buffer, whereas pellet is first 
suspended in 1% SDS and mixed with Laemmli buffer before 
loading onto 10% SDS-PAGE. Gel was allowed to run for one 
and half hour at constant voltage (160 V), after the run, the 
gel stained with coomassie blue and destained with acetic 
acid: methanol (10:50), and photographed.
2.9. In vitro phopshorylation and oligomerization of Hsp90
  Phosphorylation of purified Hsp90 was carried out by 
incubating 5 毺g of protein in 35 毺L of kinase buffer (20 mM 
Tris-HCl, pH 7.2, 20 mM KCl, 10 mM MgCl2, 60 mM NaCl, 
10 mM sodium metabisulfate, 20 mM 毬-glycerophosphate, 
6 mM EDTA, 6 mM p-nitro-phenyl-phosphate, and 
1 mM dithiothreitol) containing 7 毺Ci of[毭-32P] ATP 
and 1 unit of casein kinase II for 15 min at 37 曟.  The 
dephosphorylation was achieved by treating Hsp90 with calf 
intestine alkaline phosphatase under respective buffering 
conditions provided by the manufacturer (Promega). 
Phosphorylation and dephosphorylations were confirmed 
by presence or absence of radioactivity (assayed by liquid 
scintillation counting). Hsp90 oligomerization was induced 
by subjecting the native Hsp90 protein purified from rat liver 
to heat stress at 42 曟 for 20 min, oligomers were resolved on 
4% native acrylamide gel, oligomerization was confirmed 
and the oligomerized Hsp90 protein used for subsequent 
experiments. 
2.10. Luciferase renaturation assay 
  Luciferase was dissolved in stability buffer supplied by the 
manufacturer (Sigma) at a concentration of 0.5 mg/mL and 
denatured by heat shock at 41 曟 for 10 min. Diluted rabbit 
reticulocyte lysate (10 毺L) was dispensed to a 96-well plate 
(NUNC) and the refolding reaction was initiated by injecting 
10 毺L of the denatured luciferase mix to each well to give 
the following final concentrations: 20 mM Tris pH 7.7, 3 mM 
ATP, 5 mM creatine phosphate, 2.0 mM Mg(OAc)2, 75 mM 
KCl, 0.2 mg/mL CPK (creatine phospho kinase) and 1.5 毺g/mL 
denatured luciferase. Plates were centrifuged for one min to 
assure complete mixing of the components. After incubation 
at room temperature for 3 h, luciferase activity was measured 
by injection of 40 毺L of assay buffer (75 mM Tricine-HCl 
(pH 7.8), 24 mM MgSO4, 0.3 mM EDTA, 2 mM DTT, 313 毺M 
D-luciferin, 640 毺M coenzyme A, 0.66 mM ATP, 150 mM 
KCl, 10% (v/v) Triton X-100, 20% (v/v) glycerol and 3.5% 
DMSO). Light emission from each well was read with a 10 
sec integration time using a Perkin-Elmer EnVision 2101 
plate reader. To study actin interference, 2 毺g of F-actin or 
globular actin (G-actin) or both were used. ATP or apyrase 
enzyme was used as controls in place of 17AAG. 
2.11. Citrate synthase renaturation assay
  Chaperone activity was determined by the citrate synthase 
(CS) assay and the procedure was similar to luciferase 
assay except that CS aggregation was measured with light 
scattering at 360 nm for 30 min using spectrophotometer 
(Perkin Elmer). First 2 mg/mL CS was denatured by 8 M urea 
and 40 mM DTT treatment for 20 min, and the light scattering 
obtained was recorded. The denatured CS was diluted (1:50) 
with Tris.Cl buffer, pH 7.6 and the Hsp90 chaperone activity 
assays were performed at least thrice with preparations from 
independent purifications. Oxidized glucose-6-phosphate 
dehydrogenase (GAPDH) was used to compare the Hsp90 
selective chaperoning functions with actin and citrate 
synthase. Commercially available GAPDH (2 mg/mL; Sigma) 
in 10 mM Hepes buffer (pH 7.6) was subjected to oxidation 
with 5 mM FeSO4 and used. 
2.12. In vitro actin motility assay and epifluorescence 
microscope
  Actin filament movement on myosin-coated surface was 
studied in the presence and absence of Hsp90. The flow-
through chamber was made sandwiched with two coverslips 
coated with heavy meromyosin (HMM; Sigma). The flow 
cell was first equilibrated with an HMM buffer (100 毺g/mL, 
25 mM KCl, 25 mM Imidazole, 1 mM EGTA, 4 mM MgCl2, 
1 mM DTT, pH 7.4). Then, the same buffer, to which 0.5 mg/mL 
bovine serum albumin was added, was perfused through 
the cell to remove unbound HMM and to block any exposed 
nitrocellulose. Actin filaments (60 ng/mL) were labeled 
with tetramethyl rhodamine-phalloidin (Molecular Probes, 
Eugene) in assay buffer (25 mM KCl, 25 mM Imidazole, 1 mM 
EGTA, 4 mM MgCl2, 1 mM DTT, pH 7.4) was introduced into 
the flow cell. The buffer contained an oxygen scavenger 
system (0.1 mg/mL glucose oxidase, 0.018 mg/ml catalase, 
2.3 mg/mL glucose) to retard photobleaching. Finally, 100 毺L 
of assay buffer containing 1.0 mM ATP was flushed through 
the flow cell to initiate actin-filament motion. Actin filament 
velocities were determined by computer assisted program 
attached to the laser scanning confocal microscope. All 
experiments were performed at 30 曟. Five micro moles of 
purified Hsp90 or 17AAG was added to the flow cell to study 
the actin motility inhibition.
2.13. Statistical analysis 
  Data presented as means依SD of minimum of three 
independent experiments unless otherwise indicated, and 
analyzed with Student’s t test and a P value <0.05 was 
accepted significance. P values represented are, * for P< 0.05, 
** for P< 0.01, *** for P<0.001.
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3. Results
3.1. Hsp90 inhibition accelerates detergent induced cell lysis 
and induces cytoskeletal destabilization
  Partial cell lysis was adapted to assess the cellular 
integrity. The neuroblastoma cells after 17AAG treatment 
were subjected to mild detergent lysis, and the percent LDH 
release was measured. The detergent concentration was 
standardized in such a way that it induces a minimum of 10% 
cell lysis in untreated cells. We observed a gradual increase 
in released LDH levels after 17AAG treatment which was 
concentration dependent. A 2 毺M 17AAG treatment showed 
38% cell lysis (Figure 1A; P< 0.001) that was increased to 
65% in a 10 毺M concentration. These results suggested 
17AAG affects the cellular integrity. Since cellular integrity 
is associated with intact cytoskeleton, we first examined 
for cell morphology after the drug treatment, and observed 
altered cell morphology. Further to examine whether cell 
morphological alterations are due to gross re-arrangements 
of actin filaments, cells were stained with rhodmaine 
phalloidin and observed under a fluorescence microscope. 
A conspicuous destabilization of actin-cytoskeleton was 
observed after 17AAG treatment with change of a definite 
actin bundling at the plasma membrane to distorted F-actin 
arrays moving away from the plasma membrane (Figure 1B). 
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Figure 1. Geldanamycin induced effects on cellular integrity and 
actin-cytoskeleton. 
A: Geldanamycin induced enhancement of detergent induced cell 
lysis. B: Geldanamycin induced cell morphology and destabilization of 
actin cytoskeleton. 
3.2. The in vitro binding assay of purified Hsp90 and 
filamentous actin
  We adapted in vitro spin-down assay to examine actin 
interaction with Hsp90. The purpose of this assay is to obtain 
a quantitative value of actin polymer for Hsp90 binding. 
Hsp90 and actin proteins were purified as explained in 
materials and methods. From in vitro sedimentation assay, 
we observed only functional Hsp90 binding to F-actin, 
however mutated Hsp90 did not show F-actin binding. 
Besides, functional Hsp90 has also co-precipitated with 
G-actin, however with a threefold difference with F-actin. 
More interestingly, though mutant Hsp90 failed to show any 
interaction with F-actin, it showed interaction with G-actin 
(Figure 2A).
3.3. Effect of Hsp90 biochemical modification on actin co-
precipitation
  To examine whether functional Hsp90 is obligatory for 
F-actin binding, we studied the effect of 17AAG (36 毺M) and ATP 
(5 mM) on actin binding. The drug and ATP concentrations 
were standardized such that they inhibit in vitro chaperone 
activity of Hsp90 by at least 90% in a glucose-6-phosphate 
dehydrogenase (GAPDH) renaturation assay with re-
constituted Hsp90 chaperone system (data not shown). 
These drugs were included in the assay mixture to inhibit 
Hsp90 and examined for Hsp90 binding to actin. Neither 
17AAG nor ATP was found to interfere with F-actin binding 
to Hsp90 (Figure 2B) suggesting Hsp90 binding to F-actin 
could be independent of its chaperone activity. Hsp90 
is a phosphoprotein and its phosphorylation is linked to 
chaperone activity, hence in the present study, Hsp90 
was in vitro phosphorylated by casein kinase system as 
explained in materials and methods and phosphorylated 
Hsp90 was examined for actin binding. An increased 
binding of phosphoryled Hsp90 to F-actin was observed 
and in contrary, the dephopshorylation showed no effect on 
actin binding. The phosphorylation also failed to persuade 
G-actin binding with Hsp90 (Figure 2C). 
  Hsp90 is a dimeric protein with two independent substrate 
and ATP binding sites and its oligomerization was shown 
to enhance Hsp90 activity, therefore we examined Hsp90 
oligomerization on F-actin binding. Hsp90 oligomerization 
was induced by heat stress as explained in materials and 
methods and oligomerization was confirmed by resolving the 
protein on a native gel (Figure 2D). The dimers and oligomers 
of Hsp90 were examined for F-actin binding. Compared to 
Hsp90 dimers, Hsp90 oligomers showed enhanced F-actin 
binding (Figure 2E) with a 0.5 fold (P<0.001) increase in Hsp90 
protein and 1.6 fold (P<0.001) increase in F-actin (Figure 2F).
3.4. Actin interferes with Hsp90 chaperone function
  In a pure system, it is difficult to evaluate functional 
significance of protein-protein interaction. Therefore we 
extended our study to understand the functional significance 
of Hsp90 interaction with F-actin using rabbit reticulocyte 
lysate (RRL) as chaperone system in the refolding assay of 
thermally unfolded luciferase. In control system the recovery 
obtained was maximum 93% in a 4 h time interval, whereas 
depletion of ATP using apyrase enzyme has completely 
inhibited its recovery. The reaction mixture supplemented 
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with G-actin inhibited luciferase refolding by a large extent 
(67%) whereas filamentous actin (F-actin) inhibited this 
by 53% (P<0.05), and the combination of F- and G-actin 
accelerated the inhibition of luciferase refolding by 82% 
(Figure 3A). Since luciferase refolding assay was an end-point 
measurement, which will not provide information on kinetic 
behavior of Hsp90 and actin interaction, we adapted citrate 
synthase refolding assay. We observed that F-actin more 
specifically interferes with citrate synthase renaturation 
compared to G-actin.  Between G- and F-actin, 14% 
increased interference was observed with F-actin (Figure 3B).
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Figure 2. Hsp90 and actin in vitro binding assays. 
P-pellet fraction; S-supernatant fraction. A: The in vitro co-
precipitation assay to examine actin binding to functional (wt Hsp90) 
and mutant Hsp90 (mt Hsp90).  B: nhibition of Hsp90 chaperone 
function on F-actin binding. C: Hsp90 phosphorylation effect on 
actin binding. D, E, and F: Effect of Hsp90 oligomerization on actin 
binding.
3.5. Hsp90 impedes actin motility on myosin coated plates
  The renaturation experiments provided information on 
actin interference with Hsp90 chaperone activity but not on 
actin function. In a cellular system actin along with motor 
protein, myosin contracts, thus, mimics the simplified model 
of muscle force and motion generation. In the present study, 
we examined the effect of Hsp90 on actomyosin motor assay. 
In this assay, actin filament velocities were determined by 
computer assisted software and plotted as percent actin 
filament motility. Actin velocities were compared with 
functional Hsp90, mutated Hsp90 (吟ATP), ATP and 17AAG 
supplements. We observed that Hsp90 addition to the 
reaction mixture decreased actin velocity by 52% (P< 0.01), 
and the mixture of Hsp90 and 17AAG reduced this inhibition 
to 28% (P<0.05). The mutated Hsp90 was found to be 
ineffective to impede actin motility on myosin coated plate 
(Figure 4A).
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Figure 3.  Analysis of actin binding and interference in Hsp90 
functional assay.
A: Actin interference in the Hsp90 induced luciferase refolding. B: 
Kinetic analysis of Hsp90 mediated citrate synthase renaturation and 
actin interference.
3.6. The F-actin binding assay with normal and tumor 
Hsp90
  From the studies above, one would argue that in vitro 
conditions tested with purified Hsp90 may not be the same 
with in vivo status. Therefore, we purified Hsp90 from 
using ATP-sepharose column from human neuroblastoma 
cells, and examined for F-actin binding. More than two 
fold increase of F-actin binding to Hsp90 was observed 
compared to normal cells (Figure 4B). 
3.7. 17AAG induces time-dependent effect on actin-
cytoskeleton: a kinetic analysis
  Oregon green is more photo-stable and exhibit less pH 
sensitivity compared to rhodmaine-phalloidin which was 
used in our earlier experiments (Figure 1B), therefore in the 
present experiment rhodmaine phalloidin was replaced 
with oregon green phalloidin. Decreased F-actin arrays 
and actin bundling was observed by 6 h 17AAG treatment. 
More significantly we observed disappearance of stiffened 
F-actin filaments into irregular and curved filaments 
with reduced actin bundling. By 12 h 17AAG treatment 
cells lost their original architecture which exhibited 
constricted actin-cytoskeleton with massively re-organized 
F-actin arrays, and at this time interval, F-actin bundles 
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are majorly restricted to the plasma membrane. A 24 h 
treatment showed re-appearance of actin bundling and 
F-actin arrays, however, actin recruitment and periphery 
distribution was completely lost in tumor cells at this time 
interval. Additionally, we found lamellipodia formation with 
branched actin filaments in place of actin bundling (Figure 5). 
We evaluated 17AAG effect on other transformed cell types 
such as human cervical cancer cells, human glial cells and 
human T-lymphocytes (data not presented), and obtained 
similar results suggesting that F-actin re-organization 
induced by Hsp90 inhibition was not cell type specific.
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Figure 4. Analysis of Hsp90 binding and interference in acto-myosin 
motility assay and comparative analysis of Hsp90-actin binding 
between normal and tumor cells. 
A: Analysis of actin motility on myosin coated surface and interference 
of Hsp90 in the motility. B: Actin binding assay of Hsp90 purified 
from normal and tumor cells. 
3.8. Effect of EGF and cytochalasin D on actin-cytoskeleton
Control
6 h
12 h
24 h
6 h
12 h
24 h
6 h
12 h
24 h
17AAG
EGF
cytochalasin D
oregon green
phaltoldin magnificationDAPI merge
Figure 5. Comparison of 17AAG, EGF, and cytochalasin D induced 
actin cytoskeleton alterations in human neuroblastoma tumor cells. 
  Epidermal growth factor (EGF) stimulates actin 
polymerization whereas actin polymerization inhibitor 
cytochalasin D inhibits the same. We examined the 
effect of EGF and cytochalasin D on neuroblastoma either 
alone or in combination. EGF treatment stimulated actin 
polymerization exhibiting branched F-actin arrays and its 
accumulation. Although EGF treatment has induced actin 
cytoskeleton ruffling, it also enhanced actin bundles on cell 
periphery. The cytochalasin D treatment has induced actin-
depolymerization that resulted in extensive loss of F-actin 
arrays and actin-bundling. The cytochalasin D combination 
with EGF resulted in the retention of 50% of actin polymers, 
and this could be due to the titration effect of EGF on 
cytochalasin D induced depolymerization after the treatment 
(Figure 6).
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Figure 6. Combinatorial effect induced cytoskeleton alterations in 
human neuroblastoma cells. 
3.9. Effect of 17AAG on EGF and cytochalasin D 
combination
  The 17AAG effect was found to be prominent in 
destabilizing actin-cytoskeleton, which may relate to the 
inhibition of actin polymerization or decreased actin content 
by 17AAG. An extended actin bundles were observed in a 
time-dependent manner with EGF combination. Similarly 
cytochalasind D induced loss of actin fibers are retained by 
EGF combination. When we used cytochalasin D and 17AAG 
cells lost complete cytoarchitecture due to severe loss and 
damage to the actin-cytoskeleton (data not shown). A triple 
combination of 17AAG with EGF and cytochalasin D showed 
lack of actin cytoskeletal recovery even after prolonged 
incubation i.e. 24 h. These observations suggested that 
17AAG potentiates the effect of cytoskeletal disruptors, and 
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this effect is not reversible. In our study, 17AAG combination 
with cytochalasin D resulted in drug induced synergism in 
both deploymerizing actin and decreasing its content (Figure 
6). 
4. Discussion
  The major finding of the present study is to demonstrate 
the significance of Hsp90 involvement in the maintenance 
of tumor cell integrity through stabilizing the actin 
cytoskeleton. We demonstrate that Hsp90 interacts with 
F-actin and stabilizes the actin cytoskeleton in tumor 
cells. We provide information on two important facets, 
(1) in a cellular system 17AAG induces loss of cellular 
integrity through actin cytoskeletal destabilization, (2) in 
a pure system Hsp90 binds to F-actin and only Hsp90 
oligomerization appears to enhance actin binding.
  Considering the highly organized cytoskeletal proteins and 
induced expression of Hsp90 in tumor cells, we construe 
that Hsp90 may be associated with the cytoskeleton. It was 
shown that Hsp90 inhibition using geldanamycin induces a 
significant change in membrane polarization and membrane 
order[23,24]. The cortical F-actin near the plasma membrane 
is responsible for providing the structural integrity of 
the cell as well as provide substratum for generating the 
forces of cellular protrusions, thus actin filament depletion 
affects transmembrane bending stiffness and equilibrium 
curvature[25,26]. Although detergent induced cell lysis 
after 17AAG treatment may not infer 17AAG’s direct effect 
on membrane integrity, provided information that 17AAG 
treatment sensitizes tumor cells to detergent treatment. 
The distortion of plasma membrane integrity was further 
associated with destabilization of actin cytoskeleton. Our 
findings signify that there was not only a decrease in tension 
of actin filaments but loss. Thus, 17AAG probably involved 
in localized relaxation detachment of cortical-cytoskeleton 
from the plasma membrane. 
  Our findings demonstrate that Hsp90 binds to both G- 
and F-actin, however, Hsp90 binding to F-actin especially 
in tumor cells found to be more alluring. Further, except 
oligomerization, no other functional modification of Hsp90 
showed alterd actin binding. Mapping of actin binding 
motifs suggested lack of specific actin binding motifs 
through which Hsp90 can interact with actin[27]. Studies 
in vitro, while allowing defined conditions, suffer from 
limitations imposed by an artificial environment. However, 
F-actin interference with luciferase and citrate synthase 
renaturations added that F-actin binding to Hsp90 may not 
be through pure hydrophobic interactions as proposed[28]. 
F-actin assembles with myosin filaments composed of heavy 
and light chains to form a protein complex that uses energy 
from ATP hydrolysis to power actin-myosin contraction[29]. 
Acto-myosin motility assays revealed that Hsp90 binding 
to actin are not mediated by surface exposed hydrophobic 
regions and therefore argues against any false interpretation. 
In addition we now have demonstrated that Hsp90 binding 
to F-actin is specific to tumor cells, which may be related to 
the functional status of Hsp90 protein. 
  The Hsp90 inhibition induced effects on actin-cytoskeleton 
includes (1) loss of laterally extended F-actin arrays that are 
in close proximity to the plasma membrane, and (2) distorted 
bundling of F-actin arrays from straightened actin filaments 
to twisted/curved form. Prolonged treatment with 17AAG 
(24 h) showed reappearance of F-actin arrays but that 
were not in the periphery to plasma membrane but small-
spread veins loosely fitted within the cytoplamsic radius. 
In addition, 17AAG also induced lamellipodia formation 
on prolonged incubation, however lamellipodia formation 
may not be significant for cell motility since lamellipodia 
are rarely observed in cancer cells[30]. The 17AAG induced 
effects are found to be not cell type specific since these 
effects were also found in other transformed cells. 
  EGF stimulates actin nucleation and filament number 
increase in experimental models[31]. A decrease in F-actin 
bundling and stress fiber formation in combination with 
17AAG suggested that Hsp90 may be indispensible for stress 
fiber formation and F-actin bundling in tumor cells. Though 
EGF stimulation was shown to enhance cell proliferation 
and migration through enhanced actin polymerization[31], 
we observed a surpassing effect of 17AAG even under 
conditions of EGF stimulation. Although it was demonstrated 
that the cellular pool of actin in the polymerized state is 
not significantly decreased upon cytochalasin D treatment, 
the disintegration of stress fibers and loss of F-actin arrays 
and bundles were quite significantly observed in our study. 
Interestingly, though cytochalasin D treatments were 
reversible after 24 h (data not presented) its combination 
with 17AAG resulted in drug induced synergism and found 
to be irreversible. The triple combination experiments using 
EGF, cytochalasin D and 17AAG also confirms irrersible 
effect of 17AAG combination with cytochalasin D.
  To enhance the antitumor potential, anticancer drugs 
are used in combination with certain cytoskeletal 
disruptors[32,33]. Cytoskeleton disruptors lack selectivity 
towards tumor cells, hence may affect both normal and tumor 
cells. Unlike many anticancer drugs, anti-Hsp90 drugs 
exhibit tumor selectivity[34,35]. Our findings demonstrate 
that Hsp90 inhibition either alone or in combination with 
cytoskeletal disruptors induces irreversible damage to the 
actin-cytoskeleton.
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